MichaelS.BlaissMD
Allergy & Immunology • Roswell, GAExecutive Medical Director, American College of Allergy, Asthma, and Immunology
Dr. Blaiss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1090 Windfaire Pl
Roswell, GA 30076Phone+1 901-674-6075
Education & Training
Tulane UniversityFellowship, Allergy and Immunology, 1980 - 1982
University of TennesseeResidency, Pediatrics, 1978 - 1979- University of TennesseeResidency, Pediatrics, 1977 - 1977
University of Tennessee Health Science Center College of MedicineClass of 1976
Certifications & Licensure
GA State Medical License 2012 - 2025
TN State Medical License 1977 - 2018
MS State Medical License 2004 - 2016- American Board of Allergy and Immunology Allergy & Immunology
- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
- Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology
Publications & Presentations
PubMed
- 81 citationsThe Childhood Asthma Control Test∗: Retrospective determination and clinical validation of a cut point to identify children with very poorly controlled asthmaAndrew H. Liu, Robert S. Zeiger, Christine A. Sorkness, Nancy K. Ostrom, Bradley E. Chipps
The Journal of Allergy and Clinical Immunology. 2010-08-01 - 129 citationsICON: chronic rhinosinusitisClaus Bachert, Ruby Pawankar, Luo Zhang, Chaweewan Bunnag, Wytske Fokkens
The World Allergy Organization Journal. 2014-10-27 - 3118 citationsAllergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)Jean Bousquet, N. Khaltaev, Alvaro A. Cruz, Judah A. Denburg, W. J. Fokkens
Allergy. 2008-04-01
Press Mentions
A New Treatment for Severe Allergic Reactions — Without the NeedleAugust 19th, 2024- U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for AdolescentsJanuary 25th, 2023
- Covid-19: Ciclesonide Failed to Accelerate Recovery in Mild DiseaseNovember 25th, 2021
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
